22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
07:00 , Oct 1, 2015 |  BC Innovations  |  Product R&D

Escaping the liver

Having addressed one of the two big problems of RNAi delivery - getting therapeutic levels of the molecules inside cells - Arrowhead Research Corp. now believes it has solved the second, with a modification to...
00:57 , Sep 12, 2015 |  BC Extra  |  Clinical News

Arrowhead chooses RNAi candidate for ccRCC

Arrowhead Research Corp. (NASDAQ:ARWR) gained $0.68 (12%) to $6.40 on Friday after it selected ARC-HIF2 as its first development candidate using the company's dynamic polyconjugate (DPC) platform for RNAi delivery to tissues outside the liver....